Stream Link: https://www.pharmacytimes.org/pages/obesity-panel-entry
This activity is supported by an educational grant from Lilly.
Program Description:
Despite its growing prevalence and the availability of FDA-approved therapies, obesity remains undertreated in the US. Persons navigating obesity care face a complex set of challenges that extend well beyond clinical criteria, including weight stigma encountered in health care settings, limited access to and affordability of newer agents, uncertainty about long-term treatment expectations, and high rates of discontinuation driven by adverse effects and inadequate counseling support. This panel discussion brings together multidisciplinary faculty to examine the evidence base for GLP-1 RA, dual GIP/GLP-1 RA therapies, and emerging therapies; explore strategies for overcoming barriers to access and medication-taking behaviors; and model the interprofessional communication and collaborative decision-making that supports optimal, person-centered obesity care. The discussion will encompass how to balance pharmacotherapy and intensified lifestyle interventions, navigate access and affordability barriers, and support persons with obesity through the sustained behavioral and clinical needs of long-term treatment. This activity will include videos of a person with obesity, faculty perspectives, as well as a case-based workshop to support best practices to apply insights to real-world clinical scenarios, equipping pharmacists to advocate for persons with obesity at every stage of their treatment journey. Participants will be provided with a Train-the-Trainer toolkit that includes resources to support the delivery of person-centered obesity care and management.
Target audience: Community Pharmacists, Health-System Pharmacists
Type of activity: Application
Release date: August 27, 2026
Expiration date: October 27, 2026
Time to complete activity: 1.5 hours
Learner level: Foundational, Intermediate
Fee: Free
Educational
Objectives:
At the completion of this activity, participants will be able to:
- Analyze real-world patterns of clinical inertia in obesity pharmacotherapy, including factors contributing to delayed initiation and under-intensification of GLP-1 RA and dual GIP/GLP-1 RA therapies
- Explore strategies for addressing weight bias, treatment access, and delivering culturally competent counseling to support shared decision-making and person-centered care
- Apply evidence-based strategies to overcome system- and patient-level barriers, manage adverse effects, and support lifestyle modifications in persons initiating or maintaining GLP-1 RA and dual GIP/GLP-1 RA therapies for obesity
- Determine best practices for communication, counseling, and education for obesity pharmacotherapy initiation and maintenance that reflect the roles of pharmacists within multidisciplinary care teams
Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP
Professor of Pharmacy Practice/Director of Cardiometabolic Services
Massachusetts College of Pharmacy and Health Sciences/Well Life Medical
Boston, MA
Diana Isaacs, PharmD, BCACP, BC-ADM, CDCES, FADCES, FCCP
Endocrine Clinical Pharmacy Specialist
Director, Education & Training in Diabetes Technology
Co-Director, Endocrine Disorders in Pregnancy
Cleveland Clinic Endocrinology & Metabolism Institute
Cleveland, OH
Robert Kushner, MD, MS
Professor Emeritus, Departments of Medicine and Medical Education
Northwestern University Feinberg School of Medicine
Chicago, IL
Anne M. Komé, PharmD, CPP, BCACP, CDCES
Endocrinology Clinical Pharmacist Practitioner
University of North Carolina Medical Center
Chapel Hill, NC
Accreditation Information
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hour (0.15 CEU) under the ACPE universal activity number 0290-0000-26-223-L01-P. The activity is available for CE credit through October 26, 2026.
Instructions for Completing the Activity and Receiving CPE Credit
To
receive CPE credit, participants must complete the pretest, review the activity in
its entirety, complete the posttest, and complete the online activity
evaluation. After successful completion of the online activity evaluation, you
can submit your credit to CPE Monitor. You may view your credit within 48 hours
at www.mycpemonitor.net. All participants must request credit before the
activity expiration date. CE credit will not be issued after this date.
Disclosures
Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, has the following relevant financial relationships with ineligible companies to disclose: Speakers Bureau: Abbott Diabetes, Amgen, CeQur, Lilly, Novo Nordisk, Xeris.
Diana Isaacs, PharmD, BCACP, BC-ADM, CDCES, FADCES, FCCP, has the following relevant financial relationships with ineligible companies to disclose: Speakers Bureau: Abbott, CeQur, Dexcom, Insulet, Lilly, Novo Nordisk, Sanofi, Sequel Pharma.
Robert Kushner, MD, MS, has the following relevant financial relationships with ineligible companies to disclose: Consultant: AbbVie, Antag, AstraZeneca, Boehringer Ingelheim, Currax, Eli Lilly, Novo Nordisk, Structure Therapeutics, Viking Therapeutics, Weight Watchers
Anne M. Komé, PharmD, CPP, BCACP, CDCES, has the following relevant financial relationships with ineligible companies to disclose: Consultant: Eli Lilly and Company; Speakers Bureau: Dexcom Incorporated; Adviser: Camurus, Crinetics Pharmaceuticals
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not
constitute any form of professional advice or referral. Discussions concerning
drugs, dosages, and procedures may reflect the clinical experience of the
author(s) or they may be derived from the professional literature or other
sources and may suggest uses that are investigational in nature and not
approved labeling or indications. Participants are encouraged to refer to
primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
Privacy Policy and Terms of Use Information: